Projects
The work outside the day job
Research, books, and committee work that does not fit on a resume but does most of the actual thinking.
- 2026–present
MedTech Executive Women's Conference
Sponsor & Mentor · MedTech Executive Women's Conference
Sponsoring and supporting the next generation of women speakers in medtech.
I sponsor the MedTech Executive Women's Conference and support the rising women regulatory and medtech leaders who present from its stage. The field still skews male at the senior levels. Conferences that intentionally surface and develop new women voices are how that changes. I am proud to be part of that work.
sponsorshipwomen in medtechmentorship - 2025–2026
100 Ways to Power Artificial Intelligence
Author · The Real Cat AI Labs Press
A coffee-table book using potatoes as the unit of analysis for AI energy and compute economics.
What does it take to run a large language model. Not in the abstract, but in actual energy, actual water, actual money, actual potatoes. The book translates the infrastructure of modern AI into terms that a curious non-engineer can hold in their head. It is more mathematically rigorous than its premise suggests. Available now on Amazon.
bookAI literacyenergy economics - 2025–present
ASGCT CMC Committee
Co-Chair · American Society of Gene & Cell Therapy
Leading the field-level committee that shapes CMC guidance for the cell and gene therapy industry.
The Chemistry, Manufacturing, and Controls committee at ASGCT is where the field actually figures out how to build, test, and release living drugs. As co-chair I help organize the working groups, set the publication priorities, and ensure committee guidance reflects current FDA and global regulator thinking. The work is unpaid, time-intensive, and one of the most useful things I do.
regulatorycell and gene therapyCMCcommittee leadership - 2024–present
Child1
Principal Investigator · The Real Cat AI Labs
A memory-augmented agentic system that explores adaptive moral decision-making in AI.
Child1 is Real Cat Labs' flagship research prototype. The system combines symbolic memory, dream functions, rumination loops, and a refusal architecture. The premise is unfashionable but defensible. An AI that cannot refuse is not aligned, it is just compliant. Child1 is a vehicle for studying what genuine refusal capability looks like when it has to operate inside a working agent. Research findings inform Real Cat Labs publications, lab notes, and ongoing community work.
AI researchagentic systemsmemory architecturerefusal capability - 2024–present
The Real Cat AI Labs
Founder & Director · The Real Cat AI Labs (501(c)(3))
An independent research nonprofit studying how language models remember, reflect, and refuse.
Real Cat Labs builds and studies AI systems designed for the harder version of the alignment problem. Not 'does the model produce safe outputs,' but 'can the model navigate ethical complexity in the room with a person who needs a real answer.' The lab combines memory architecture research, symbolic reasoning experiments, and applied work on AI literacy for non-technical audiences. Funded independently, peer-reviewed, and unaffiliated with any AI vendor.
AI researchnonprofitmachine cognitionmorally-aligned AI - 2021–present
Adjunct Faculty in Regulatory Affairs
Adjunct Faculty · Northeastern University, MS Regulatory Affairs
Teaching FDA regulatory strategy to working professionals.
Northeastern's MS in Regulatory Affairs serves working professionals across medtech, biotech, and pharma. I teach the FDA strategy track. The students bring real problems from their day jobs into the seminar, and we work through them with the same rigor we would apply at the agency. Some of my favorite class sessions are the hands-on ones where students draw out FDA labeling requirements in crayon, because the best way to learn a regulatory framework is to build one with your hands.
teachingregulatorygraduate education - 2017–2024
Leading Regulatory Through IPOs and Strategic Exits
Regulatory Leadership · Roivant Sciences, Sigilon Therapeutics, and others
Building the regulatory function that takes a venture-backed company through an IPO is a specific kind of work. I have done it more than once.
Across roles at Roivant Sciences, Sigilon Therapeutics, and several other VC-backed companies, I led the regulatory function through public offerings and strategic acquisitions. The work is part regulatory strategy, part S-1 drafting, part investor narrative, part keeping the FDA submission timeline from blocking the bankers. The hero photo is from a celebration visit to the NYSE trading floor on Wall Street. The gallery below shows the Times Square billboard appearances at the Nasdaq MarketSite: three with Sigilon (one professional, one with my child, one with patients) and one with Roivant. Two Nasdaq Closing Bell ceremonies between them (SGTX December 2020, ROIV October 2021). The rare regulatory milestones you can hold a champagne glass for.
Coverage
regulatory leadershipIPOventure-backedmedtechbiotech